News &
Publications

Contacts

Lisa Bailey
Interim Director of Communications
Director of Social Networking
215-214-3954
215-872-5846 (cell phone)
Lisa.Bailey@fccc.edu

Diana Quattrone
Director of Media Relations
215-728-7784
215-815-7828 (cell phone)
Diana.Quattrone@fccc.edu

Communications Staff

 

News

Two Fox Chase Cancer Center Researchers Share 25th Annual Bristol-Myers Squibb Award For Distinguished Achievement in Cancer Research

Robert C Young, MD
Robert C Young, MD

PHILADELPHIA (April 9, 2002) -- Robert C. Young, MD, president of Fox Chase Cancer Center, and Robert F. Ozols, MD, PhD, senior vice president for medical science at Fox Chase, have been selected to receive 25th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for their research in ovarian cancer. Young and Ozols were chosen by an independent selection committee of researchers chaired by Nobel laureate Leland H. Hartwell, PhD, president of Fred Hutchinson Cancer Center.

Young and Ozols have had a major impact on treatment and research in ovarian cancer over the last 20 years. Their work has had a direct impact on therapy for women with early-stage and advanced-stage ovarian cancer and has led to an increased understanding of the factors associated with the development of ovarian cancer and how tumors become resistant to treatment.

Robert F Ozols, MD, PhD
Robert F Ozols, MD, PhD

Young and Ozols developed a chemotherapy regimen that is the current worldwide standard for patients with advanced ovarian cancer. In addition, they conducted translational studies that have provided the framework for much of the current research on ovarian cancer. As a result of their work, women with ovarian cancer are living longer. The studies they initiated have led to more effective therapy and, ultimately, may help prevent ovarian cancer.

At Fox Chase, Young and Ozols have established an internationally-recognized program in ovarian cancer that brings together clinicians, geneticists, and basic researchers, all focused on identifying strategies to treat and prevent this disease more effectively. In addition, Ozols is principal investigator for a five-year National Cancer Institute grant for a Specialized Program of Research Excellence (SPORE) in prevention, diagnosis and treatment of ovarian cancer. Awarded in 1999, this Fox Chase SPORE grant was one of only four for ovarian cancer research and the only one on the East Coast. It focuses on research projects designed to translate basic research findings from the laboratory to clinical settings.

"Dr. Ozols and I have had an incredible scientific relationship that has spanned two decades," Young said. "We have worked hard and remain dedicated to research related to eradicating this insidious disease. I am delighted to share this honor with my friend and colleague.

"The award is an honor, but more importantly is the fact that women with ovarian cancer have benefited from this combined clinical and laboratory effort," Ozols said.

Young and Ozols will each receive a $25,000 cash prize and a silver medallion at a dinner in their honor at the New York Palace Hotel in New York City on April 18, 2002.

The Bristol-Myers Squibb Unrestricted Biomedical Research Grants Program that provides the Cancer Award was initiated in 1977. The program currently provides no-strings-attached funding in six biomedical research areas, including cardiovascular, infectious diseases, metabolic diseases, neuroscience, nutrition, and cancer research. The Distinguished Achievement Award of $50,000 is awarded annually in each of the seven categories.

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.


Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Media inquiries only, please contact Diana Quattrone at 215-728-7784.

More 2002 News Releases »